Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 13/20 | 0.60 |
| ▸ | CHUK | O15111 | 4/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3392499 | 0.93 | IKBKB (0.58) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3396422 | 0.89 | IKBKB (0.74) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3395375 | 0.88 | IKBKB (0.46) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3391327 | 0.88 | IKBKB (0.59) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3395708 | 0.87 | IKBKB (0.64) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3792017 | 0.86 | IKBKB (0.81) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3392932 | 0.86 | IKBKB (0.53) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3390020 | 0.86 | IKBKB (0.52) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3396620 | 0.82 | IKBKB (0.73) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3390482 | 0.81 | IKBKB (0.64) | IKBKBCHUKAURKAFLT3CSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501780-B2 | Indazole carboxamides and their use | GLAXOSMITHKLINE LLC (US) | 2013-08-06 | — | — | US | claimed |
| US-20070281933-A1 | Novel Indazole Carboxamides And Their Use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-06 | — | — | US | claimed |
| US-8501780-B2 | Indazole carboxamides and their use | GLAXOSMITHKLINE LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501780-B2 | Indazole carboxamides and their use | GLAXOSMITHKLINE LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501780-B2 | Indazole carboxamides and their use | GLAXOSMITHKLINE LLC (US) | 2013-08-06 | — | — | US | disclosed |
| EP-1758578-B1 | NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE | GLAXOSMITHKLINE LLC (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-1758578-B1 | NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE | GLAXOSMITHKLINE LLC (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-1758578-A4 | NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE | SMITHKLINE BEECHAM CORP (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20070281933-A1 | Novel Indazole Carboxamides And Their Use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281933-A1 | Novel Indazole Carboxamides And Their Use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281933-A1 | Novel Indazole Carboxamides And Their Use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-06 | — | — | US | disclosed |
| EP-1758578-A2 | NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE | Smithkline Beecham Corporation (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006002434-A2 | NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281933-A1 | Novel Indazole Carboxamides And Their Use | IKBKG, IRAK2, NFKBIA | IKBKB 8/4885CHUK 9/4885AURKA 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.